BACKGROUND AND OBJECTIVES: ESRD is associated with substantial cognitive deficits but whether earlier kidney dysfunction predicts cognitive decline is less well defined. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: More than 1700 women aged ≥70 years in the Nurses' Health Study had plasma creatinine and urinary albumin/creatinine ratios (ACRs) measured in 2000, within 12 months of their initial cognitive testing. These participants had repeated assessments of cognition administered by phone every 2 years, including tests for general cognition, verbal memory, verbal fluency, and working memory for up to 6 years of follow-up. Mixed-effects regression analysis was applied to calculate mean differences in the rate of cognitive decline between women with an estimated GFR <60 ml/min per 1.73 m(2) or an ACR ≥5 mg/g versus referent levels. RESULTS: The median age was 74 years at initial cognitive testing, 99% of women were Caucasian, median plasma creatinine was 0.8 mg/dl, and 25% had an ACR ≥5 mg/g. The difference in cognitive decline with a baseline ACR ≥5 mg/g versus an ACR <5 mg/g was equivalent to the difference observed with 2-7 years of aging; that is, a higher ACR was associated with 2-7 times faster decline in all four cognitive domains assessed (all P values <0.05) than that attributed to each 1 year of aging alone. No associations were observed between an eGFR <60 ml/min per 1.73 m(2) and cognitive decline. CONCLUSIONS: A baseline urinary ACR ≥5 mg/g, a level not traditionally considered clinically significant, is independently associated with faster decline in cognitive function.
BACKGROUND AND OBJECTIVES:ESRD is associated with substantial cognitive deficits but whether earlier kidney dysfunction predicts cognitive decline is less well defined. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: More than 1700 women aged ≥70 years in the Nurses' Health Study had plasma creatinine and urinary albumin/creatinine ratios (ACRs) measured in 2000, within 12 months of their initial cognitive testing. These participants had repeated assessments of cognition administered by phone every 2 years, including tests for general cognition, verbal memory, verbal fluency, and working memory for up to 6 years of follow-up. Mixed-effects regression analysis was applied to calculate mean differences in the rate of cognitive decline between women with an estimated GFR <60 ml/min per 1.73 m(2) or an ACR ≥5 mg/g versus referent levels. RESULTS: The median age was 74 years at initial cognitive testing, 99% of women were Caucasian, median plasma creatinine was 0.8 mg/dl, and 25% had an ACR ≥5 mg/g. The difference in cognitive decline with a baseline ACR ≥5 mg/g versus an ACR <5 mg/g was equivalent to the difference observed with 2-7 years of aging; that is, a higher ACR was associated with 2-7 times faster decline in all four cognitive domains assessed (all P values <0.05) than that attributed to each 1 year of aging alone. No associations were observed between an eGFR <60 ml/min per 1.73 m(2) and cognitive decline. CONCLUSIONS: A baseline urinary ACR ≥5 mg/g, a level not traditionally considered clinically significant, is independently associated with faster decline in cognitive function.
Authors: H C Gerstein; J F Mann; Q Yi; B Zinman; S F Dinneen; B Hoogwerf; J P Hallé; J Young; A Rashkow; C Joyce; S Nawaz; S Yusuf Journal: JAMA Date: 2001-07-25 Impact factor: 56.272
Authors: D A Bennett; R S Wilson; J A Schneider; D A Evans; L A Beckett; N T Aggarwal; L L Barnes; J H Fox; J Bach Journal: Neurology Date: 2002-07-23 Impact factor: 9.910
Authors: Johannes B Scheppach; Josef Coresh; Aozhou Wu; Rebecca F Gottesman; Thomas H Mosley; David S Knopman; Morgan E Grams; A Richey Sharrett; Silvia Koton Journal: Am J Kidney Dis Date: 2020-05-16 Impact factor: 8.860
Authors: Barry I Freedman; Kaycee M Sink; Christina E Hugenschmidt; Timothy M Hughes; Jeff D Williamson; Christopher T Whitlow; Nicholette D Palmer; Michael E Miller; Laura C Lovato; Jianzhao Xu; S Carrie Smith; Lenore J Launer; Joshua I Barzilay; Robert M Cohen; Mark D Sullivan; R Nick Bryan; Benjamin C Wagner; Donald W Bowden; Joseph A Maldjian; Jasmin Divers Journal: Am J Kidney Dis Date: 2017-06-23 Impact factor: 8.860
Authors: Joshua I Barzilay; Timothy M Morgan; Anne M Murray; R Nick Bryan; Jeff D Williamson; Adrian Schnall; Lenore J Launer Journal: J Gerontol A Biol Sci Med Sci Date: 2015-11-19 Impact factor: 6.053
Authors: Kay Deckers; Ileana Camerino; Martin P J van Boxtel; Frans R J Verhey; Kate Irving; Carol Brayne; Miia Kivipelto; John M Starr; Kristine Yaffe; Peter W de Leeuw; Sebastian Köhler Journal: Neurology Date: 2016-12-14 Impact factor: 9.910